{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:08:35Z","timestamp":1789214915736,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.therap.2026.07.006","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:28:16Z","timestamp":1788190096000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bupr\u00e9norphine et gestion de la douleur\u00a0: mise au point clinique et rep\u00e8res pratiques"],"prefix":"10.1016","author":[{"given":"Julien","family":"Cabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Chappuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Duale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2393-7061","authenticated-orcid":false,"given":"C\u00e9lian","family":"Bertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2026.07.006_bib0360","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jpain.2022.08.008","article-title":"Systematic review and meta-analysis of the prevalence of chronic pain among patients with opioid use disorder and receiving opioid substitution therapy","volume":"24","author":"Delorme","year":"2023","journal-title":"J Pain"},{"key":"10.1016\/j.therap.2026.07.006_bib0365","doi-asserted-by":"crossref","first-page":"641430","DOI":"10.3389\/fpsyt.2021.641430","article-title":"Prevalence and characteristics of chronic pain in buprenorphine and methadone-maintained patients","volume":"12","author":"Delorme","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2026.07.006_bib0370","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fpsyt.2018.00335","article-title":"Chronic pain opioid-maintained patients receive less analgesic opioid prescriptions","volume":"9","author":"Delorme","year":"2018","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2026.07.006_bib0375","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.3390\/jcm12175575","article-title":"Long-acting buprenorphine formulations as a new strategy for the treatment of opioid use disorder","volume":"12","author":"Maremmani","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.therap.2026.07.006_bib0380","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1476-5381.1977.tb07532.x","article-title":"Agonist and antagonist properties of buprenorphine, a new antinociceptive agent","volume":"60","author":"Cowan","year":"1977","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.therap.2026.07.006_bib0385","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction","volume":"35","author":"Jasinski","year":"1978","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.therap.2026.07.006_bib0390","first-page":"S17","article-title":"French field experience with buprenorphine","volume":"13","author":"Auriacombe","year":"2004","journal-title":"Am J Addict"},{"key":"10.1016\/j.therap.2026.07.006_bib0395","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-024-02128-y","article-title":"Buprenorphine pharmacodynamics: a bridge to understanding buprenorphine clinical benefits","volume":"85","author":"Davis","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.therap.2026.07.006_bib0400","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/ALN.0b013e318238fea0","article-title":"Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active","volume":"115","author":"Brown","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.therap.2026.07.006_bib0405","series-title":"Medical Pharmacology and Therapeutics","first-page":"3","article-title":"Principles of pharmacology and mechanisms of drug action","author":"Waller","year":"2018"},{"key":"10.1016\/j.therap.2026.07.006_bib0410","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jsps.2016.07.002","article-title":"An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice","volume":"25","author":"Salahudeen","year":"2017","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.therap.2026.07.006_bib0415","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0022-3565(24)29653-1","article-title":"Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations","volume":"297","author":"Seifert","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.therap.2026.07.006_bib0420","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0165-6147(93)90129-8","article-title":"Partial agonists, full agonists, antagonists: dilemmas of definition","volume":"14","author":"Hoyer","year":"1993","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.therap.2026.07.006_bib0425","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.therap.2026.07.006_bib0430","first-page":"S14","article-title":"D\u00e9c\u00e8s en lien avec la prise d\u2019opiac\u00e9s\/opio\u00efdes \u00e0 partir des enqu\u00eates DRAMES et DTA","volume":"36","author":"Eysseric","year":"2024","journal-title":"Toxicol Anal Clin"},{"key":"10.1016\/j.therap.2026.07.006_bib0435","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world","volume":"8","author":"Lofwall","year":"2014","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2026.07.006_bib0440","doi-asserted-by":"crossref","first-page":"765","DOI":"10.7326\/0003-4819-85-6-765","article-title":"Naloxone","volume":"85","author":"Martin","year":"1976","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.therap.2026.07.006_bib0445","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid \u03bc receptor binding constants for selected opioid drugs","volume":"59","author":"Volpe","year":"2011","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.therap.2026.07.006_bib0450","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002130100920","article-title":"Blockade of hydromorphone effects by buprenorphine\/naloxone and buprenorphine","volume":"159","author":"Strain","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.therap.2026.07.006_bib0455","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-3565(25)20047-7","article-title":"Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans","volume":"247","author":"Bickel","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.therap.2026.07.006_bib0460","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3949\/ccjm.90a.23022","article-title":"A practical guide for buprenorphine initiation in the primary care setting","volume":"90","author":"Le\u00f3n-Barriera","year":"2023","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.therap.2026.07.006_bib0465","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/phar.2676","article-title":"Buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review","volume":"42","author":"Spreen","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2026.07.006_bib0470","first-page":"859","article-title":"Buprenorphine: an attractive opioid with underutilized potential in treatment of chronic pain","volume":"8","author":"Khanna","year":"2015","journal-title":"J Pain Res"},{"key":"10.1016\/j.therap.2026.07.006_bib0475","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jpainsymman.2013.03.001","article-title":"Buprenorphine","volume":"45","author":"Foster","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.therap.2026.07.006_bib0480","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.therap.2026.07.006_bib0485","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/00912709922008236","article-title":"Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations","volume":"39","author":"Nath","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.therap.2026.07.006_bib0490","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000456612","article-title":"Randomised comparison of a novel buprenorphine oral lyophilisate versus existing buprenorphine sublingual tablets in opioid-dependent patients: a first-in-patient phase II randomised open label safety study","volume":"23","author":"Strang","year":"2017","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2026.07.006_bib0495","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on \u03bc-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.therap.2026.07.006_bib0500","series-title":"National clinical guidelines and procedures for the use of buprenorphine in the treatment of opioid dependence","author":"Lintzeris","year":"2006"},{"key":"10.1016\/j.therap.2026.07.006_bib0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy","volume":"144","author":"Greenwald","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2026.07.006_bib0510","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0893-133X(00)00110-X","article-title":"Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study","volume":"23","author":"Zubieta","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.therap.2026.07.006_bib0515","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s00213-005-0023-6","article-title":"Buprenorphine\/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers","volume":"181","author":"Comer","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.therap.2026.07.006_bib0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2020.05.008","article-title":"Bupr\u00e9norphine d\u2019action prolong\u00e9e\u00a0: quelles perspectives pour la pratique clinique\u00a0?","author":"Chappuy","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2026.07.006_bib0525","series-title":"Sixmo EPAR overview","year":"2025"},{"key":"10.1016\/j.therap.2026.07.006_bib0530","series-title":"Buvidal\u00a0: r\u00e9sum\u00e9 des caract\u00e9ristiques du produit","year":"2018"},{"key":"10.1016\/j.therap.2026.07.006_bib0535","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/jcph.665","article-title":"Population pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder","volume":"56","author":"Laffont","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.therap.2026.07.006_bib0540","series-title":"Buvidal: assessment report","year":"2018"},{"key":"10.1016\/j.therap.2026.07.006_bib0545","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jss.2023.03.021","article-title":"Acute pain management in traumatically injured patients with outpatient buprenorphine therapy","volume":"289","author":"Culshaw","year":"2023","journal-title":"J Surg Res"},{"key":"10.1016\/j.therap.2026.07.006_bib0550","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDccon2300275","article-title":"How do I manage acute pain for patients prescribed buprenorphine for opioid use disorder?","volume":"3","author":"Sandhu","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.therap.2026.07.006_bib0555","doi-asserted-by":"crossref","first-page":"155261","DOI":"10.1016\/j.jcrc.2025.155261","article-title":"Evaluation of opioid requirements in mechanically ventilated patients taking buprenorphine\/naloxone prior to admission","volume":"91","author":"O\u2019Connell","year":"2025","journal-title":"J Crit Care"},{"key":"10.1016\/j.therap.2026.07.006_bib0560","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/ALN.0000000000005291","article-title":"Continuation versus interruption of buprenorphine\/naloxone in adult veterans undergoing surgery: examination of postoperative pain and opioid utilization in a national retrospective cohort study","volume":"142","author":"Hitt","year":"2025","journal-title":"Anesthesiology"},{"key":"10.1016\/j.therap.2026.07.006_bib0565","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/jcph.2286","article-title":"Buprenorphine continuation during critical illness associated with decreased inpatient opioid use in individuals maintained on buprenorphine for opioid use disorder in a retrospective study","volume":"63","author":"Quaye","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.therap.2026.07.006_bib0570","doi-asserted-by":"crossref","first-page":"558","DOI":"10.7326\/ANNALS-24-01917","article-title":"Acute pain management in people with opioid use disorder","volume":"178","author":"Buonora","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.therap.2026.07.006_bib0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain: United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"},{"issue":"Suppl. 1","key":"10.1016\/j.therap.2026.07.006_bib0580","first-page":"1","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020\u00a0focused update","volume":"14","author":"Kampman","year":"2020","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2026.07.006_bib0585","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/AJP.0000000000000996","article-title":"Postoperative pain and opioid dose requirements in patients on sublingual buprenorphine: a retrospective cohort study for comparison between postoperative continuation and discontinuation of buprenorphine","volume":"38","author":"Komatsu","year":"2022","journal-title":"Clin J Pain"},{"key":"10.1016\/j.therap.2026.07.006_bib0590","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.2147\/JPR.S475351","article-title":"Pathophysiology of pain and mechanisms of neuromodulation: a narrative review (a neuron project)","volume":"17","author":"Karcz","year":"2024","journal-title":"J Pain Res"},{"key":"10.1016\/j.therap.2026.07.006_bib0595","series-title":"M\u00e9decine de la douleur\u00a0: m\u00e9canismes physiologiques et pathologiques de la douleur et de l\u2019analg\u00e9sie","author":"Poisbeau","year":"2025"},{"key":"10.1016\/j.therap.2026.07.006_bib0600","series-title":"Bon usage des m\u00e9dicaments opio\u00efdes\u00a0: antalgie, pr\u00e9vention et prise en charge du trouble de l\u2019usage et des surdoses","year":"2022"},{"key":"10.1016\/j.therap.2026.07.006_bib0605","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ajad.13396","article-title":"Patients\u2019 experiences with continuation or discontinuation of buprenorphine before painful procedures: a brief report","volume":"32","author":"Hathaway","year":"2023","journal-title":"Am J Addict"},{"key":"10.1016\/j.therap.2026.07.006_bib0610","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1007\/s11606-020-06115-3","article-title":"Treating perioperative and acute pain in patients on buprenorphine: narrative literature review and practice recommendations","volume":"35","author":"Buresh","year":"2020","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.therap.2026.07.006_bib0615","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/rapm-2021-103007","article-title":"Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel","volume":"46","author":"Kohan","year":"2021","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.therap.2026.07.006_bib0620","series-title":"Interim brief clinical guidelines for use of depot buprenorphine (Buvidal\u00ae and Sublocade\u00ae) in the treatment of opioid dependence","author":"McDonough","year":"2020"},{"key":"10.1016\/j.therap.2026.07.006_bib0625","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/bjaed\/mkw049","article-title":"Perioperative management of opioid-tolerant patients","volume":"17","author":"Simpson","year":"2017","journal-title":"BJA Educ"},{"key":"10.1016\/j.therap.2026.07.006_bib0630","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bja.2017.11.086","article-title":"Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomised controlled trials","volume":"120","author":"White","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.therap.2026.07.006_bib0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rapm-2024-106014","article-title":"Buprenorphine versus full agonist opioids for acute postoperative pain management: a systematic review and meta-analysis of randomized controlled trials","volume":"51","author":"Hickey","year":"2026","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.therap.2026.07.006_bib0640","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jss.2024.06.024","article-title":"Perioperative management of buprenorphine at an urban academic medical center","volume":"302","author":"Brighton","year":"2024","journal-title":"J Surg Res"},{"key":"10.1016\/j.therap.2026.07.006_bib0645","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/dar.14005","article-title":"Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open-label, non-randomised trial of long-acting injectable buprenorphine treatment in Australian custodial settings","volume":"44","author":"White","year":"2025","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.therap.2026.07.006_bib0650","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/10398562241295872","article-title":"Effectiveness of long-acting buprenorphine: a systematic review","volume":"33","author":"McMaster","year":"2025","journal-title":"Australas Psychiatry"},{"key":"10.1016\/j.therap.2026.07.006_bib0655","series-title":"Adjuvant Analgesics","article-title":"Toward a rational taxonomy of analgesic drugs","author":"Lussier","year":"2015"},{"key":"10.1016\/j.therap.2026.07.006_bib0660","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00000542-200510000-00020","article-title":"Intraoperative epidural analgesia combined with ketamine provides effective preventive analgesia in patients undergoing major digestive surgery","volume":"103","author":"Lavand\u2019homme","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.therap.2026.07.006_bib0665","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.2147\/JPR.S305146","article-title":"Benefit-risk analysis of buprenorphine for pain management","volume":"14","author":"Hale","year":"2021","journal-title":"J Pain Res"},{"key":"10.1016\/j.therap.2026.07.006_bib0670","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/jcpt.12196","article-title":"The clinical analgesic efficacy of buprenorphine","volume":"39","author":"Raffa","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.therap.2026.07.006_bib0675","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. TEMGESIC 0,2mg, comprim\u00e9 sublingual: r\u00e9sum\u00e9 des caract\u00e9ristiques du produit. Saint-Denis; 1987. Mis \u00e0 jour 2024. https:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/notice\/N0426640.htm. [Consult\u00e9 le 20\u00a0juillet 2026]."},{"key":"10.1016\/j.therap.2026.07.006_bib0680","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/ADM.0000000000000965","article-title":"Acute Pain management for a tibial plateau fracture shortly after a buprenorphine XR depot injection: a case report","volume":"16","author":"Sivanathan","year":"2022","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2026.07.006_bib0685","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/08897077231167043","article-title":"Perioperative management of extended-release buprenorphine: a narrative review and case series","volume":"44","author":"Hickey","year":"2023","journal-title":"Subst Abuse"},{"key":"10.1016\/j.therap.2026.07.006_bib0690","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1097\/ADM.0000000000001024","article-title":"Perioperative management of extended-release buprenorphine","volume":"17","author":"Hickey","year":"2023","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2026.07.006_bib0695","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11916-024-01286-8","article-title":"Methadone and buprenorphine in the perioperative setting: a review of the literature","volume":"28","author":"Foglia","year":"2024","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.therap.2026.07.006_bib0700","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12871-024-02703-6","article-title":"Perioperative pain management interventions in opioid user patients: an overview of reviews","volume":"24","author":"Vadeghani","year":"2024","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.therap.2026.07.006_bib0705","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1097\/ADM.0000000000001136","article-title":"Inpatient low-dose transitions from full agonist opioids including methadone onto long-acting depot buprenorphine: case series from a multicenter clinical trial","volume":"17","author":"Seval","year":"2023","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2026.07.006_bib0710","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/ADM.0000000000001333","article-title":"Early long-acting buprenorphine for opioid use disorder in the setting of acute pain","volume":"18","author":"Schindle","year":"2024","journal-title":"J Addict Med"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:25:11Z","timestamp":1789212311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595726000910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":71,"alternative-id":["S0040595726000910"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2026.07.006","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bupr\u00e9norphine et gestion de la douleur\u00a0: mise au point clinique et rep\u00e8res pratiques","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2026.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}